AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A process for obtaining cryoprecipitable proteins comprising:
(a) contacting a composition of cryprecipitable protein(s) of interest with a stabilizing and solubilizing formulation comprising a mixture of arginine, at least one hydrophobic amino acid and trisodium phosphate; and
(b) transforming said protein(s) composition into a freeze-dried form; and
(c) performing a virus inactivation step by heat treatment of said freeze-dried proteins.
~~including a virus inactivation step by heat treatment of a freeze-dried form of said proteins, characterized in that it includes, before transforming the proteins into a freeze-dried form, an initial step of addition, to said proteins, of a stabilizing and solubilizing formulation comprising a mixture of arginine, at least one hydrophobic amino acid and trisodium phosphate.~~

2. **(Currently Amended)** A process according to claim 1, characterized in that the formulation ~~is constituted~~consists essentially of the said mixture of arginine, at least one hydrophobic amino acid and trisodium phosphate.

3. **(Currently Amended)** A process according to claim 1, ~~characterized in that the~~wherein arginine is present in a concentration of from 25 to 50 g/l.

4. **(Currently Amended)** A process according to claim 3, ~~characterized in that~~wherein the concentration of arginine is of from 35 to 45 g/l.

5. **(Currently Amended)** A process according to claim 1, ~~characterized in that~~wherein the trisodium citrate is present in a concentration of from 0.5 to about 12 g/l.

6. **(Currently Amended)** A process according to claim 1, ~~characterized in that~~wherein the hydrophobic amino acid is leucine, iso-leucine or a mixture thereof.

7. **(Currently Amended)** A process according to claim 6, ~~characterized in that~~wherein leucine, iso-leucine or mixture thereof are present in a concentration of from 5 to 15 g/l.

8. **(Currently Amended)** A process according to claim 6, ~~characterized in that~~wherein the concentration of leucine or iso-leucine or mixture thereof is of from 9 to 11 g/l.

9. **(Currently Amended)** A process according to claim 1, ~~characterized in that~~ wherein the formulation of step (a) further contains glycine and/or lysine ~~are added to the formulation~~.

10. **(Currently Amended)** A process according to claim 9, ~~characterized in that~~wherein glycine and lysine are each present in a concentration of from 1 to 5 g/l.

11. **(Currently Amended)** A process according to claim 9, ~~characterized in that~~wherein each of these concentrations of glycine and lysine is of from 1.5 to 2.5 g/l.

12. **(Currently Amended)** A process according to claim 1, ~~characterized in that~~wherein the freeze-drying of step (b) is carried out at temperatures between -40°C and -30°C for 48 hours.

13. **(Currently Amended)** A process according to claim 1, ~~characterized in that~~wherein the heat treatment of virus inactivation of step (c) is carried out at temperatures between 80°C and 90°C for 72 hours.

14. **(Currently Amended)** A process according to claim 1, ~~characterized in that it~~ further comprising ~~comprises~~, prior to step (a), ~~addition of the stabilizing and solubilizing formulation to a liquid composition of cryoprecipitable proteins,~~ at least one ~~additional~~ step of virus inactivation and/or elimination from the said ~~liquid~~ composition of cryoprecipitable protein(s) by solvent-detergent and/or by nanofiltration on filters of 35 nm.

15. **(Previously Presented)** A process according to claim 1, characterized in that it is applicable to all cryoprecipitable proteins.

16. **(Previously Presented)** A process according to claim 1, characterized in that it is applicable to at least one of the proteins selected from Factor VIII, von Willebrand Factor, Factor XIII, fibrinogen and fibronectin.

17. **(Currently Amended)** A concentrate of at least one cryoprecipitable protein comprising the stabilizing and solubilizing formulation in combination with ~~added to said~~ at least one protein prepared by the process according to claim 1.

18. **(Currently Amended)** A concentrate according to claim 17 intended ~~to~~ for therapeutic use.

19. **(Currently Amended)** A concentrate according to claim 17, ~~consisting of a reconstituted freeze-dried fibrinogen obtained by the process according to claim 13, in order to~~ presenting a filterability of about 2 ml/cm² on a filter with a porosity of 0.20 ± 0.02 μm.

20. **(Cancelled)**

21. **(Cancelled)**